Citations

Showing 10 of 108152 citations.

Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease
Gastel, Maatje D.A. van , Edwards, Marie E., Torres, Vicente E. , Gansevoort, Ron T. , Kline, Timothy L. , Torres, Vicente E , Erickson, Bradley J.

Mayo Clinic

Journal of the American Society of Nephrology | July 3, 2019 | Volume: 30 | Issue: 8 | Pages: 1514-1522

10.1681/asn.2018090902 | PMID 31270136 Get It

Significance Statement Because renal function often remains stable in the early stages of autosomal dominant polycystic kidney disease (ADPKD), total kidney volume (TKV) is the most important biomarker of disease severity and progression. The authors developed and validated a fully automated method of simultaneously measuring TKV and total liver volume (TLV) as well as their growth rates from magnetic resonance images. Their findings indicate that the method’s performance is equivalent to the gold standard of manual tracing while requiring a fraction of the time and skill. This approach may address the unmet need for rapid and reliable assessment of TKV and TLV, allowing identification of patients with rapidly progressing ADPKD for emerging drug treatments and serving as a reliable alternative for assessment of disease progression in clinical trials. Background The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. Methods We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method’s performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. Results TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and −1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and −1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. Conclusions These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.
Individualized Delay for Abdominal Computed Tomography Angiography Bolus-Tracking Based on Sequential Monitoring: Increased Aortic Contrast Permits Decreased Injection Rate and Lower Iodine Dose
Gutjahr, Ralf , Lee, Yong S. , Halaweish, Ahmed F., Suresh, Vighnesh , Weber, Nikkole M. , Vrtiska, Terri J., Williamson, Eric E. , Schmidt, Bernhard , Fletcher, Joel G. , McCollough, Cynthia H.

Mayo Clinic

Journal of Computer Assisted Tomography | July 3, 2019 | Volume: 43 | Issue: 4 | Pages: 612-618

10.1097/rct.0000000000000874 | PMID 31268876 Get It

Objective The aim of this study was to determine if computed tomography (CT) angiography using an individualized transition delay (CTA-ID) would facilitate reductions in injection rate and iodine dose. Methods The CTA-ID was performed in 20 patients with routine injection rate and iodine dose; 20 patients with injection rate lowered by 1 mL/s; and 40 patients with injection rate lowered by 1 mL/s with 29% less iodine. Routine CTAs in the same or size-matched patients served as controls. Diagnostic image quality and intra-arterial CT numbers were assessed. Results The median transition delay between aortic threshold and CTA-ID image acquisition was significantly longer than with conventional bolus tracking (mean increase, 13.3 seconds; P < 0.0001), with image quality being the same or better. Intra-arterial CT numbers were 200 Hounsfield units or greater for 80 of 80 CTA-ID, but not for 6 of 49 (12%) internal control or for 11 of 80 (14%) size-matched control patients. Conclusion The CTA-ID bolus-tracking software alters transition delays to permit diagnostic CTA examinations despite slower injection rate and less iodine.
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
Gertz, Morie A. , Scheinberg, Morton , Drachman, Brian, Khella, Sami, Whelan, Carol , Obici, Laura , Gertz, Morie A , Obici, Laura , Waddington‐Cruz, Márcia , Heitner, Stephen B. , Karam, Chafic

Mayo Clinic

Expert Review of Clinical Pharmacology | July 3, 2019 | Volume: 12 | Issue: 8 | Pages: 701-711

10.1080/17512433.2019.1635008 | PMID 31268366 Get It

Pigmented Macular Lesion in a Child
Chodnicki, Kevin D. , Brodsky, Michael C., Olsen, Timothy W.

Mayo Clinic

JAMA Ophthalmology | July 3, 2019 | Volume: 137 | Issue: 9 | Pages: 1076

10.1001/jamaophthalmol.2019.1659 | PMID 31268517 Get It

Palliative Inotrope Therapy
Chuzi, Sarah , Allen, Larry A. , Warraich, Haider J. , Dunlay, Shannon M.

Mayo Clinic

JAMA Cardiology | July 3, 2019 | Volume: 4 | Issue: 8 | Pages: 815

10.1001/jamacardio.2019.2081 | PMID 31268467 Get It

A new study in contrasts: brain MRI for the depiction of tumor metabolism
Kaufmann, Timothy J.

Mayo Clinic

Neuro-Oncology | July 3, 2019 | Volume: 21 | Issue: 9 | Pages: 1095-1096

10.1093/neuonc/noz121 | PMID 31271202 Get It

Fenestrated adipofascial reverse flap for the reconstruction of fingertip amputations
Oliver, Jeremie D. , Sisti, Andrea , Oliver, Jeremie D , Sisti, Andrea , Nisi, Giuseppe

Mayo Clinic

Microsurgery | July 3, 2019 | Volume: 39 | Issue: 6 | Pages: 575-575

10.1002/micr.30480 | PMID 31268559 Get It

Clinical evaluation of fitness to drive in patients with brain metastases
Gorelkin, Vanessa C, Mrugała, Maciej M. , Vora, Sujay A., Ashman, Jonathan B. , Daniels, T.B., Halyard, Michele Y. , Rule, William G., Butterfield, Richard , Porter, Alyx B. , Valencia-Sánchez, Cristina , Daniels, Thomas B, Butterfield, Richard J, Schild, Steven E. , Sharma, Akanksha , Zhang, Nan

Mayo Clinic

Neuro-Oncology Practice | July 3, 2019 | Volume: 6 | Issue: 6 | Pages: 484-489

10.1093/nop/npz027 | PMID 31832219 Get It

Abstract Background Guidelines to provide recommendations about driving restrictions for patients with brain metastases are lacking. We aim to determine whether clinical neurologic examination is sufficient to predict suitability to drive in these patients by comparison with an occupational therapy driving assessment (OTDA). Methods We prospectively evaluated the concordance between neurology assessment of suitability to drive (pass/fail) and OTDA in 41 individuals with brain metastases. Neuro-oncology evaluation included an interview and neurological examination. Participants subsequently underwent OTDA during which a battery of objective measures of visual, cognitive, and motor skills related to driving was administered. Results The mean age of patients who failed OTDA was age 68.9 years vs 59.3 years in the group members who passed (P = .0046). The sensitivity of the neurology assessment to predict driving fitness compared with OTDA was 16.1% and the specificity 90%. The 31 patients who failed OTDA were more likely to fail Vision Coach, Montreal Cognitive Assessment, and Trail Making B tests. Conclusions There was poor association between the assessment of suitability to drive by neurologists and the outcome of the OTDA in patients with brain metastases. Subtle deficits that may impair the ability to drive safely may not be evident on neurologic examination. The positive predictive value was high to predict OTDA failure. Age could be a factor affecting OTDA performance. The results raise questions about the choice of assessments in making recommendations about driving fitness in people with brain metastases. OTDA should be strongly considered in patients with brain metastases who wish to continue driving.
Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease
Cannone, Valentina , Cabassi, Aderville , Volpi, Riccardo , Burnett, John C.

Mayo Clinic

International Journal of Molecular Sciences | July 3, 2019 | Volume: 20 | Issue: 13 | Pages: 3265

10.3390/ijms20133265 | PMID 31269783 Get It

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.